Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine

Published:2022-07-28 Issue:4 Volume:387 Page:374-376
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Launay Odile¹,Cachanado Marine²,Luong Nguyen Liem B.³,Ninove Laetitia⁴,Lachâtre Marie³,Ben Ghezala Inès,Bardou Marc^ORCID,Schmidt-Mutter Catherine⁵^ORCID,Lacombe Karine⁶,Laine Fabrice,Allain Jean-Sébastien^ORCID,Botelho-Nevers Elisabeth⁷,Tavolacci Marie-Pierre⁸,Chidiac Christian⁹,Pavese Patricia¹⁰,Dussol Bertrand¹¹,Priet Stéphane⁴,Deplanque Dominique¹²,Touati Amel²,Curci Laureen,Konate Eleine,Ben Hamouda Nadine,Besbes Anissa,Nubret Eunice¹³,Capelle Florence¹³,Berard Laurence,Rousseau Alexandra,Tartour Eric¹⁴,Simon Tabassome⁶,de Lamballerie Xavier⁴

Affiliation:

1. Université Paris Cité, Paris, France

2. Hôpital St. Antoine, Paris, France

3. Hôpital Cochin, Paris, France

4. Aix-Marseille University, Marseille, France

5. Hôpitaux Universitaires de Strasbourg, Strasbourg, France

6. Sorbonne Université, Paris, France

7. CHU de Saint-Etienne, Saint-Etienne, France

8. CHU Rouen, Rouen, France

9. Hospices Civils de Lyon, Lyon, France

10. CHU de Grenoble Alpes, Grenoble, France

11. Hôpitaux Universitaires de Marseille, Marseille, France

12. CHU Lille, Lille, France

13. Assistance Publique–Hôpitaux de Paris, Paris, France

14. Hôpital Européen Georges Pompidou, Paris, France

Funder

Ministry of Health and Solidarity

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMc2206711

Reference4 articles.

1. Audio Interview: Do We Need New Covid-19 Vaccines?

2. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

3. Homologous and Heterologous Covid-19 Booster Vaccinations

4. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing;International Journal of Biological Macromolecules;2024-10

2. Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARS-CoV-2 mRNA vaccination;iScience;2024-08

3. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity;Journal of Virology;2024-07-23

4. Heterologous versus homologous COVID-19 booster vaccinations for adults: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials;BMC Medicine;2024-06-24

5. Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in England;eClinicalMedicine;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3